Home » Stocks » Taiwan Liposome

Taiwan Liposome Company, Ltd. (TLC)

Stock Price: $6.50 USD -0.39 (-5.66%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 264.72M
Revenue (ttm) 6.95M
Net Income (ttm) -26.83M
Shares Out 42.09M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $6.50
Previous Close $6.89
Change ($) -0.39
Change (%) -5.66%
Day's Open 6.90
Day's Range 6.40 - 6.83
Day's Volume 3,157
52-Week Range 2.47 - 8.49

More Stats

Market Cap 264.72M
Enterprise Value 237.15M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 42.09M
Float 29.70M
EPS (basic) n/a
EPS (diluted) -0.51
FCF / Share -0.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3,077
Short Ratio 0.27
Short % of Float n/a
Beta 0.98
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 38.10
PB Ratio 7.82
Revenue 6.95M
Operating Income -27.16M
Net Income -26.83M
Free Cash Flow -27.63M
Net Cash 27.57M
Net Cash / Share 0.68
Gross Margin 100.00%
Operating Margin -390.96%
Profit Margin -386.10%
FCF Margin -397.61%
ROA -45.45%
ROE -169.62%
ROIC -231.50%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(109.54% upside)
Current: 6.50
Target: 13.62
*Average 12-month USD price target from 3 stock analysts.

Financial Performance

Financial numbers in millions TWD.

Financial Overview

Revenue Growth235.57%25.56%19.1%-
Gross Profit20962.3249.6441.67
Operating Income-818-918-898-837
Net Income-808-902-874-824
Shares Outstanding64.0566.2266.22-
Earnings Per Share-24.64-28.74-31.50-29.78
Operating Cash Flow-778-686-819-608
Capital Expenditures-54.01-66.71-18.11-21.43
Free Cash Flow-832-753-837-629
Cash & Equivalents1,0241,1159521,799
Total Debt194414112116
Net Cash / Debt8307018401,683
Book Value7226699871,804
Numbers in millions TWD, except per-share numbers.

Company Profile

Company Details

Full Name Taiwan Liposome Company, Ltd.
Country Taiwan
CEO Keelung Hong

Stock Information

Ticker Symbol TLC
Stock Exchange NASDAQ
Unique Identifier NASDAQ: TLC
IPO Date November 21, 2018


Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. The company provides various product candidates that target various areas of unmet medical need in pain management, ophthalmology, and oncology. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III trial for knee osteoarthritis pain. The company's product candidates also comprises TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that is in Phase II clinical trial for post-surgical pain management; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; and TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma. Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.